Glioblastoma is the most commonly occurring malignant brain tumor, with a high mortality rate despite current treatments. Its classification has evolved over the years to include not only histopathological features but also molecular findings. Given the heterogeneity of glioblastoma, molecular biomarkers for diagnosis have become essential for initiating treatment with current therapies, while new technologies for detecting specific variations using computational tools are being rapidly developed. Advances in molecular genetics have made possible the creation of tailored therapies based on specific molecular targets, with various degrees of success. This review provides an overview of the latest advances in the fields of histopathology and radiogenomics and the use of molecular markers for management of glioblastoma, as well as the development of new therapies targeting the most common molecular markers. Furthermore, we offer a summary of the results of recent preclinical and clinical trials to recognize the current trends of investigation and understand the possible future directions of molecular targeted therapies in glioblastoma.
胶质母细胞瘤是最常见的恶性脑肿瘤，尽管现有治疗手段不断发展，其死亡率仍然居高不下。该疾病的分类体系历经演变，现已不仅涵盖组织病理学特征，更整合了分子生物学发现。鉴于胶质母细胞瘤的高度异质性，分子生物标志物诊断已成为启动现有治疗方案的关键前提，而基于计算工具检测特定变异的新技术正在快速发展。分子遗传学的进步使得针对特定分子靶点的个体化治疗成为可能，并已取得不同程度的成功。本综述系统阐述了组织病理学与放射基因组学领域的最新进展，探讨了分子标志物在胶质母细胞瘤诊疗中的应用现状，以及针对常见分子标志物的新型疗法研发动态。此外，我们通过对近期临床前及临床试验结果的总结，识别当前研究趋势，并展望分子靶向治疗在胶质母细胞瘤领域的未来发展方向。
Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma
肿瘤(癌症)患者之家